Drugs / T-cell Antigen Presenting Cells expressing truncated CD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03186118 | Aug 2017 → Sep 2021 overdue | B-cell acute lymphoblastic leukemia | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-cell Antigen Presenting Cells expressing truncated CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03186118 ↗ |
| Known as | T-APC | “T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)” NCT03186118 ↗ |
| Action | Activate | “T-APCs capable of activating CD19-specific CAR T cells for proliferation and redistribution to tissue beds where tumor cells of ALL seed” NCT03186118 ↗ |
| Modality | Cell therapy | “Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene” NCT03186118 ↗ |